Skip to main content
. 2022 May 13;11(10):1639. doi: 10.3390/cells11101639

Figure 6.

Figure 6

High levels of non-classical monocytes associate with improved PFS in patients with ER-negative primary tumors and with improved OS in patients with ER-positive primary tumors. Kaplan–Meier curves of progression-free survival (PFS; left) and overall survival (OS) from baseline (right) according to the levels of indicated monocyte subpopulation in patients with MBC stratified for primary tumor ER status. (A) CD14++CD16 classical monocytes. (B) CD14++CD16+/++ intermediate monocytes. (C) CD14+CD16++ non-classical monocytes. N = 17 ER-positive and N = 7 ER-negative for all subpopulations. Statistics by log-rank test, p-values < 0.05 highlighted in bold.